John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

Speaker 3: (00:32)
Could you give us a brief overview about your background and yourself?

 

Speaker 3: (02:16)
 Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan? 

 

Speaker 3: (05:34)
 What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?

 

Speaker 3: (08:01)
 Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?

 

Speaker 3: (10:36)

Could you elaborate on the specific clinical indications for testing in relation to irinotecan?

 

Speaker 3: (13:27)
 How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results? 

 

Speaker 3: (14:02)
 Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?